Staar Surgical Co Dossier - Source-backed chat

Staar Surgical Co

STAANASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)1.15

Intrinsic Value $38.22median of 3 methodsbased on filings through 3 Jul 2026

Market Price $22.38Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 71% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+71%)

Data confidence Sign in to view data confidence

Market Cap $1.1B

Enterprise Value $1B

Shares Outstanding 51.4M diluted

Moat Rating None

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

STAAR Surgical represents a compelling standalone turnaround story following the collapse of its proposed acquisition by Alcon in January 2026. Activist investor Broadwood Partners (holding a 31% stake) successfully blocked the merger, asserting that the $30.75 per share offer undervalued the company's long-term potential. With Broadwood now controlling the boardroom and installing three aligned directors, the company has pivoted to independent execution. Q1 2026 results validated this standalone thesis, delivering record net sales of $93.5 million (up 119.6% YoY) and a return to profitability with $5.2 million in net income. Growth is driven by robust demand in China following the commercial launch of the EVO+ ICL, double-digit growth in the U.S., and operational efficiencies. Backed by a strong balance sheet with no long-term debt, STAAR is well-positioned to capture the global shift from tissue-removal laser surgery to lens-based refractive correction.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$19.00

Mean target$27.90

High · most bullish analyst$37.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$19.0015%

The bear case reflects potential headwinds from intense competition in China, macroeconomic volatility, and geopolitical tensions in key international markets (such as the Middle East and India). If laser-based procedures regain momentum or if competitor phakic lenses gain market share, STAAR's revenue growth could slow to the single digits. Additionally, prolonged leadership uncertainty or execution delays in product rollouts could depress the stock's valuation multiple back toward historical lows.

Base CaseCentral scenario

$27.9060%

Matches the consensus mean

The base case projects steady standalone execution under the guidance of the restructured board and a newly appointed permanent CEO. Revenue growth is expected to track management's long-term target of 10% annually from 2026 through 2030. China distributor inventories remain normalized, and the U.S. market continues to gain market share despite overall sluggishness in the broader refractive surgery market. Profitability continues to improve with positive Adjusted EBITDA and gradual operating margin expansion.

Bull CaseUpside scenario

$37.0025%

The bull case assumes rapid global adoption of the EVO ICL platform, particularly in the U.S. and China. In this scenario, the commercial launch of EVO+ in China exceeds expectations, and the expanded FDA indication for patients aged 45 to 60 accelerates U.S. market penetration. Operating leverage expands significantly as Swiss manufacturing facilities scale up, avoiding tariffs and driving gross margins toward 75%+. Standalone revenue growth sustains a 15%+ CAGR through 2030, and the company attracts interest from other large medical device acquirers at a premium valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Global leader in phakic intraocular lenses with a highly differentiated, clinically-proven biocompatible Collamer technology (EVO ICL).
Strong standalone financial position with over $190 million in cash and no long-term debt, providing significant financial flexibility.
High insider conviction and alignment, highlighted by largest shareholder Broadwood Partners aggressively purchasing shares and taking active boardroom control.
Significant addressable market expansion following the FDA approval of the EVO ICL indication for patients aged 45 to 60.

Key Investment Risks

High geographic concentration, with China representing a substantial portion of total net sales, exposing the company to regional competitive and geopolitical risks.
Dependence on a single product family (EVO ICL) for the vast majority of revenues.
Macroeconomic sensitivity, as refractive surgery is typically an out-of-pocket elective procedure vulnerable to consumer spending downturns.
Leadership transition risk as the company operates under interim co-CEOs while conducting a global search for a permanent leader.

Thesis Invalidation Triggers

A sustained decline in China net sales below $35 million per quarter, indicating market share loss or severe distribution disruptions.
Failure to recruit a highly qualified permanent CEO by the end of 2026, leading to strategic drift.
A major safety or regulatory recall of the EVO lens platform that damages surgeon and patient trust.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.